Literature DB >> 18248648

Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.

Karin Frank-Raue1, Andreas Machens, Christian Scheuba, Bruno Niederle, Henning Dralle, Friedhelm Raue.   

Abstract

OBJECTIVES: Hereditary medullary thyroid carcinoma (MTC) is caused by germ-line mutations in the RET proto-oncogene. Our study addresses the difference in development of MTC between rare mutations in RET codons 790, 791 and 804.
DESIGN: We evaluated tumour stage, calcitonin levels, biochemical cure rates and associated endocrinopathies in 153 German/Austrian patients with RET 790 (n = 47), 791 (n = 56) and 804 mutations (n = 50), divided into index- and screening groups.
RESULTS: Age at diagnosis in index-patients did not differ significantly among the three codon groups (medians of 57, 61 and 53 years). Tumour stage at diagnosis was significantly less advanced with codon 791 (n = 22) than 790 (n = 16) and 804 (n = 16) mutations (P = 0.001). In screening patients, age at diagnosis did not differ significantly among the three groups (medians 19, 24 and 32 years). Tumour stage at diagnosis was also significantly less advanced with codon 791 (n = 34) than 790 (n = 31) and 804 (n = 34) (P = 0.032). Preoperative basal calcitonin levels were significantly lower in codon 791 carriers compared to codon 790 carriers, and cure rates were significantly higher in both index (75%vs. 31%; P = 0.03) and screening patients (100%vs. 75%; P = 0.015). Additional endocrinopathies were observed only with codon 791 carriers (four pheochromocytomas and two hyperparathyroidism).
CONCLUSION: There is a significant difference in MTC development with less extensive C-cell disease, higher cure rate and more frequent additional endocrinopathies in carriers of RET codon 791 mutations compared with carriers of codons 790 and 804 mutations. This information should be considered when age of prophylactic thyroidectomy is discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248648     DOI: 10.1111/j.1365-2265.2008.03215.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  16 in total

1.  Failure of pentagastrin-stimulated calcitonin testing in early manifestation of familial medullary thyroid cancer.

Authors:  Christian Pirich; Gundula Rendl; Cornelia Hauser-Kronberger; Ingrid Häusler
Journal:  Wien Klin Wochenschr       Date:  2012-09-11       Impact factor: 1.704

2.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

Review 3.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

Review 4.  [Thyroid C cells and their pathology: Part 2: Medullary thyroid carcinoma].

Authors:  S Synoracki; S T Schmid; S Ting; K W Schmid
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 5.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

Review 6.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

7.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

8.  RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest.

Authors:  Eliska Vaclavikova; Sarka Dvorakova; Vlasta Sykorova; Radovan Bilek; Katerina Dvorakova; Petr Vlcek; Richard Skaba; Tomas Zelinka; Bela Bendlova
Journal:  Endocrine       Date:  2009-10-14       Impact factor: 3.633

9.  Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.

Authors:  Shuanzeng Wei; Virginia A LiVolsi; Kathleen T Montone; Jennifer J D Morrissette; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

10.  A Case of medullary thyroid carcinoma with de novo V804M RET germline mutation.

Authors:  Young Sik Choi; Hye Jung Kwon; Bu Kyung Kim; Su Kyoung Kwon; Yo Han Park; Jeong Hoon Kim; Sang Bong Jung; Chang Hoon Lee; Seong Keun Lee; Shinya Uchino
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.